Category Archives: Clay Siegall

Dr. Clay Siegall’s Role In The Fight Against Cancer

Cancer is an illness that has affected many of us directly as well as indirectly. The illness itself can be found within the body in areas such as the lungs, liver, skin, and throat. There are various forms it also, but the fight against cancer has stepped it’s game up to another level by the introduction of Antibody Drug Conjugates. These advanced medications are far more advanced than treatments of the past. They fall under the “Antibody Based Therapy” sector of cancer research and they’ve been highly developed and tested for safe use. These therapies have the ability to spare non-targeted cells within the body while eradicating cancerous cells. This is innovation at it’s finest unlike Chemotherapy. Chemotherapy and others tend to affect all cells no matter the case. When this happens, extreme sickening of the patient will occur.

Dr. Clay Siegall and Seattle Genetics has transcended the game with their advanced (ADCETRIS) drug. ADCETRIS is one of the most successful medications on the market that has yielded some fine results. Dr. Siegall’s extensive knowledge comes from working in the industry for many years as well as having a strong passion for helpers others. He has a Ph.D in Genetics from George Washington University as well as a (BS) in Zoology from The University of Maryland. The guy just has what it takes to get things done, but did you know that Siegall is actually the company’s (CEO) and President? That’s right! He is also one of the co-founders that birthed this revolutionary institute. Seattle Genetics has the principles of:


Being such a well respected guy, Dr. Siegall is well accomplished as he holds up to 15 patents, has written over 70 publications, and is a guest speaker. The fight against this deadly disease is on and Dr. Clay Siegall is playing a crucial role in it’s demise.

Tidbits About Clay Siegall

Who is Clay Siegall?
Dr. Clay B. Siegall, Ph.D., is the co-founder, President and CEO of Seattle Genetics, Inc. He has served as President and CEO with Seattle Genetics, Inc. since 2002. Dr. Clay B. Siegall, Ph.D., is a trained scientist with a focus on cancer therapies.

What is Dr. Clay B. Siegall’s main responsibility as CEO?
Dr. Clay B. Siegall, Ph.D., guides Seattle Genetics, Inc. to be a leader in the development of antibody-drug conjugates (ADCs). Seattle Genetics secured FDA approval of its first ADC product in 2011. Seattle Genetics is also working towards the advancement ADCs for the treatment of cancer. Dr. Clay B. Siegall has also lead Seattle Genetics to enter into several strategic licenses for the company’s ADC technology. More than 20 ADCs are in clinical development using Seattle Genetics technologies. Dr. Clay B. Siegall is also responsible for capital-raising activities and securing financing for research and development.

What does the news and media say about Dr. Clay B. Siegall, Ph.D.? posted an article on 7/6/16 regarding Seattle Genetics gaining the ability to market Adcetris in Europe. The article quotes Dr. Siegall’s feelings about the enlarged market for Adcetris as well as the benefit this will bring to Europe. Overall it appears that Dr. Clay B. Siegall is mostly discussed with regard to his net worth, income, and the advanced research and technology he leads at Seattle Genetics, Inc.

Clay Siegall (Seattle Genetics’ CEO) and the Answer to Prayers

Cancer is one of the most dangerous diseases known to mankind. Over the past few decades it has replaced AIDS as the number one feared illness in the world. It’s deadliness arises from the fact that it discriminates against nothing, and can affect anyone no matter what their religion, cultural heritage or age is. Many people globally fear that they will contract cancer, or that one of their loved ones will at some point during their lifetime. One of the main reasons why it is so feared is because there is only very specific treatments for cancer, most of them coming with a host of different side effects that could also be potentially lethal. This means that current treatment in many cases is just as bad for the individual as the cancer itself. In order to try and combat cancer, and to find new and improved ways to battle it, medical scientist Clay Siegall, along with his colleagues in the scientific world, are doing all that they can to find treatment answers and a future cure for this debilitating disease.

Clay Siegall in 1998 founded Seattle genetics, and research firm that is dedicated to the sole purpose of finding the cure for cancer. Most of Seagulls time in life is dedicated to looking for different treatment avenues and antibody answers for cancer cells. If you check his company website it is obvious that many man hours are placed into research periods. Clay is a dedicated and hard working man, and the way that his company operates is a mirror of this.

There is no doubt that with Clay Siegall and his staff on the job that cancer does not stand a chance. While there has yet to be found a cure for this disease Siegall is tirelessly working to find one, and through his research there is definitely light at the end of the proverbial tunnel. Pharmaceutical giants such as Pfizer and Genetech have allied themselves with Siegall and are giving him the funding that he needs to keeping moving ever forward in his quest.

Seattle Genetics Thrives Under Leadership of Clay Siegall

Seattle Genetics is a biotechnology company that focuses on developing antibody based therapy specifically for the treatment of different forms of cancer. The company was founded in 1998 by scientist Clay B. Siegall, Ph.D and operates out of Bothell, a suburb in Seattle. Seattle Genetics specializes in developing what is known as Antibody-Drug Conjugates or ADC’s for which they have become an industry leader. ADC’s attempt to mimic the ability of monoclonal antibodies by directing agents that kill cells, straight to the cancer cells. Unlike chemotherapy, Antibody-Drug Conjugates are designed to target only cells that are cancerous, leaving surrounding non-cancerous cells unharmed. This greatly reduces the negative affects that are usually seen from chemotherapy. Brentuximab vedotin, aka ADCETRIS® is the first ADC that was developed by Seattle Genetics and has become their most impactful production yet. It was approved by the Food and Drug Administration in 2011. Seattle Genetics reached an partnership with Takeda Pharmaceutical Company to allow ADCETRIS to be sold in over 60 countries worldwide, making it their best selling product to date.

Clay B. Siegall is a co-founder of Seattle Genetics and currently resides as President, CEO and Chairman of the company. Siegall attended the University of Maryland where he earned a Bachelors in Zoology. He furthered his education at the George Washington University successfully completing a Ph. D. in Genetics. Siegall is trained as a scientist with a focus on targeted cancer therapies. Siegall’s background has been the driving force behind Seattle Genetics development of the Antibody-Drug Conjugates. Siegall has been able to guide Seattle Genetics to make more than $325 million since their inception. Before founding Seattle Genetics, Siegall worked with a number of esteemed health and research institutes. From 1991-1997, he worked with the Bristol-Myers Squibb Pharmaceutical Research Institute. After those six years, Siegall gained more critical experience at the National Institutes of Health as well as the National Cancer Institute. He has also been the recipient of several awards such as Entrepreneur of the Year granted by Pacific Northwest Ernst & Young and Alumnus of the Year for Computer, Maths and Sciences from his own University of Maryland.

Dr. Clay iegall: President and Co-founder Seattle Genetics

Dr. Clay Siegall is the co-founder at Seattle Genetics. The company was incorporated in 1998. He is the current Chief Executive Officer, President, and the Chairman of the Board. Seattle Genetics, under his leadership, has developed the most advanced pipeline of antibody-based therapies for killer diseases including cancer. Seattle Genetics, through his exclusive leadership, has also produced ADCETRIS (brentuximab bedouin). The company got permission from the United States Drug and Food Administration department to conduct this research.

Dr. Clay Siegall has also played a significant role in guiding capital-raising activities to aid Seattle Genetics. For this reason, he has secured over $675 million through private and public financing. However, this amount includes Seattle Genetic’s public initial offerings issued in 2001. Before co-founding the leading genetics research company in North America, Dr. Clay Siegall worked as the Bristol-Myers Medicinal Research Institute from 1992 to 1997. Dr. Siegall has also worked with the National Institute of Health and the United States Cancer Institute from 1987 to 1991. He is currently serving as a board member of the Alder BioPharmaceuticals. This is a privately-owned biotechnological company to foster disease counteraction. Dr. Clay Siegall has authored over 70 publications. He has more than 15 licenses in the field of Medicine.

Dr. Clay Siegall received his Ph.D. in Medicinal Genetics from the University of George Washington. He is a bachelor’s degree holder in Zoology from Maryland University. The company, Seattle Genetics, has a developed diverse portfolio in pre-clinical and clinical product candidates that target a broad range of autoimmune and cancer indications. Seattle Genetics is one of the leading providers of antibody technologies. It was voted at the anti-drug conjugate platform. Dr. Clay Siegall has guided the company fundraising campaigns which secured over $220 million through private financing. The company has also entered into strategic collaborations. One of the main partnerships entered by the corporation is the limited universal partnership agreement with Genentech. The partnership will see the acquisition of SGN-40 which is valued at $860 million. Seattle Genetics has also entered into partnerships with Medllmunne, Genentech, Curagen, Progenics, and Bayer that have generated over $65 million for cancer survivors since 2001.

Seattle Genetics Expands their Drug Pipeline to 12 More Drugs and Increases their Workforce

Clay Siegall co-founded Seattle Genetics in 1998. He serves as the President, CEO, and the Chairman of the Board at the company. Before starting his business, he worked with the Bristol-Myers Squibb Pharmaceutical Research Institute in 1991 to 1997. He also served at the National Cancer Institute and National Institutes of Health in 1988-1991.

Siegall holds 15 patents and is an author of over 70 publications. Additionally, Dr. Siegall is on the Board of Directors for the Alder Biopharmaceuticals, Mirna Therapeutics, and the Ultragenyx Pharmaceuticals. Dr. Siegall holds a BS in Zoology from the University of Maryland and a Ph.D. in Genetics from George Washington University.

Seattle Genetics operates on three principles including drug development, research, and scientific innovation. The company has a qualified team of professionals who understand the antibody technologies, and they developed the antibody-drug conjugates (ADCs) for the treatment of cancer. Through Dr. Siegall’s leadership, the company has generated over $330 million through financing by the private and public institutions including the public offering in 2001.

Additionally, the company has teamed up with Genentech for the SGN-40 and signed a collaboration agreement valued at $860 million. Since 2001, they have also made various partnerships with different companies including Genentech, CuraGen, Bayer, Progenics, and MedImmune, which generated over $65 million revenue.

Seattle Genetics seeks to expand its drug pipeline to include 12 more drugs. Currently, the Adcetris, their first ADC has received more than 70 trials testing against various types of lymphomas. The drug is in the advanced clinical trials for the treatment of newly diagnosed and previously untreated Hodgkin lymphoma. In 2015, the Adcetris sales went up to $226 million in the United States and Canada and the company expects a range of $255-275 in the drug sales in 2016.

They have also introduced the 33A drug for the treatment of the acute myeloid leukemia, which is currently in Phase 3 clinical trials. They also have a drug for the treatment of breast cancer and two for the bladder cancer. They also want to hire 100 more employees in U.S. and 20 more in their offices in Switzerland to join their 800 teams of workers in the company.

Another Step of Success for Dr. Clay Siegall

Back in January of 2013, Austin, Texas based biotechnology focused company Mirna Therapeutics confirmed that they would have a new member joining their Board of Directors. This new member was revealed to be Dr. Clay Siegall, the CEO and co-founder of Seattle Genetics who would be serving as an outside director. Mirna Therapeutics made this decision based upon their current focus on cancer research, which Dr. Siegall has plenty of experience in. Dr. Paul Lammers, the President and CEO of Mirna Therapeutics, commented on the announcement saying that they were enthusiastic having someone who has the experience that Dr. Siegall has joined their Board of Directors. Dr. Lammers has also stated his expectation of Dr. Siegall helping Mirna Therapeutics in the development of their microRNA-based therapeutics.

Seattle Genetics Co-Founder Appointed to Board of Directors for Mirna Therapeutics Inc.

About Dr. Siegall
Dr. Clay Siegall co-founded Seattle Genetics in 1998 and currently serves as the company’s President, CEO, and Chairman of the Board of Directors. It was under Dr. Siegall’s leadership that enabled Seattle Genetics to grow and become what it is today. After all, it was thanks to Dr. Siegall’s financial strategies that enabled the company to secure more than $675 million from both public and private finances. Before founding Seattle Genetics, Dr. Siegall had been part of the National Cancer Institute, National Institutes of Health (1988-1991) and then later the Bristol-Myers Squibb Pharmaceutical Research Institute (1991-1997). Dr. Siegall received his PhD in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.

About Seattle Genetics
Incorporated on July 15, 1997, the Bothell, Washington based company has been focused upon antibody based cancer treatment methods. Currently the most renown product of the company is the Brentuximab vedotin, better known under the trade name of Adcetris, which is an antibody-drug conjugate that targets the CD30 protein. Other antibody-drug conjugates from Seattle Genetics include SGN-CD19A, SGN-CD33A, SGN-LIV1A, and SGN-CD70A while ASG-22ME and ASG-15ME are still in development and being worked upon in collaboration with the company Agensys. Currently, Seattle Genetics has around 650 employees within the United States.

Keep up with Clay Siegall: